Further dissection of BAD as a molecular modulator of brain glucose sensing and its potential functional collaboration with other known glucose sensors may uncover novel insights as well as new therapeutic targets for the control of hypoglycemia caused by aggressive insulin therapy. This evidence concerns the gene BAD and Hypoglycemia.